Echinaforce Junior Bioavailability Trial

• Status: Withdrawn
• Trial end date: 2018-06-30
• Target enrollment: 0
• Participant gender: All

Summary

In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: A. Vogel AG; Bioforce AG
• Collaborator: University Children's Hospital, Zurich

Criteria

Inclusion Criteria:

• Children in the age group 4-12 years with an uncomplicated common cold (upper respiratory tract infection)

• First symptoms appeared within the last 72 hours

• Written consent given by the parents and verbal consent of children who are capable of judgement

Exclusion Criteria:

• Not able to fast 2 hours prior to the treatment

• intake of another preparation containing echinacea within the last 24 hours

• Participation in a clinical trial within the last 30 days

• any progressive systemic illness, including tuberculosis, leukemia, connective tissue diseases, multiple sclerosis, or other autoimmune diseases; or

• history of relevant allergy, including allergy to Compositae plants